Table 1 Cohort characteristics, overall and according to trimethoprim-sulfamethoxazole (TMP-SMX) use
Characteristic at the time of first rituximab treatment | Overall cohort, N = 1877 | TMP-SMX, N = 426 | No TMP-SMX, N = 1451 |
|---|---|---|---|
Age, mean (SD) | 50.9 (16) | 48.4 (15) | 51.6 (16) |
Female sex (%) | 1008 (54) | 188 (44) | 820 (57) |
Insurance type, n (%) | |||
Commercial | 1393 (74) | 345 (81) | 1048 (72) |
Medicare | 253 (14) | 37 (9) | 216 (15) |
Medicaid | 231 (12) | 44 (10) | 187 (13) |
Year of index date, n (%) | |||
2011–2015 | 898 (48) | 185 (43) | 713 (49) |
2016–2019 | 979 (52) | 241 (57) | 738 (51) |
Rituximab treatment type, n (%) | |||
Induction | 1314 (70) | 323 (76) | 991 (68) |
Maintenance | 563 (30) | 103 (24) | 460 (32) |
Healthcare use in the prior 6 months | |||
Number of physician visits, mean (SD) | 16.1 (15) | 18.5 (14) | 15.4 (14) |
≥ 20 physician visits | 577 (31) | 164 (39) | 413 (28) |
Hospital admission, n (%) | 774 (41) | 236 (55) | 538 (37) |
Intensive care unit admission, n (%) | 317 (17) | 102 (24) | 215 (15) |
Prior serious infection | 159 (9) | 48 (11) | 111 (8) |
Disease features and/or co-morbidities, n (%) | |||
Sinusitis | 491 (26) | 116 (27) | 371 (26) |
Obstructive lung disease | 393 (21) | 92 (23) | 297 (21) |
Interstitial lung disease | 90 (5) | 19 (4) | 71 (5) |
Glomerulonephritis | 208 (11) | 46 (11) | 162 (11) |
Chronic kidney disease | 435 (23) | 91 (21) | 344 (24) |
Dialysis | 172 (9) | 40 (9) | 132 (9) |
Diabetes | 273 (15) | 56 (13) | 217 (15) |
Medication use, n (%) | |||
Prednisone 1–19 mg/daya | 220 (12) | 60 (14) | 160 (11) |
Prednisone ≥ 20 mg/daya | 630 (34) | 247 (58) | 383 (26) |
Cyclophosphamideb | 61 (3) | 14 (3) | 47 (3) |
Azathioprineb | 92 (5) | 20 (5) | 72 (5) |
Methotrexateb | 202 (11) | 61 (14) | 141 (10) |
Atovaquoneb | 43 (2) | 4 (1) | 39 (3) |
Dapsoneb | 38 (2) | 3 (1) | 35 (2) |